Ushbu ishga iqtibos qilgan ishlar

1 ta ish

Ish: Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia

1. Reply to Tomasz Drewa and Piotr Chlosta's Letter to the Editor re: Frans Debruyne, Arkadij A. Gres, Dmitrii L. Arustamov. Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia. Eur Urol 2008;54:170–80

   F. Debruyne, A A Gres, D. Arustamov

   MaqolaUrinary Bladder and Prostate ResearchEuropean Urology20080 iqtibos

   ABIABI:AkademIndex/2008.article.000360